This WG will coordinate all aspects along the pipeline of drug development, including preclinical studies. All the knowledge gathered and tools developed in WG1 will serve to guide the identification of existing and new compounds that target NRF2 and influence the course of selected NCDs in cellular and animal models. WG2 will strive for standardizing procedures and protocols to maximize the reproducibility of results, and for selecting accurate disease animal models.
